Boston Medical Center

GE HealthCare to feature Mobile Mammography Screening Truck along with Latest AI Platform as part of SBI2024 Breast Cancer Imaging Showcase

Retrieved on: 
Friday, April 12, 2024
Other Consumer, Women, Other Health, Photography, Radiology, Oncology, Software, Artificial Intelligence, Medical Devices, Hospitals, Electronic Design Automation, Consumer, Technology, General Health, Biotechnology, Health, Apps, Applications, Health Technology, FDA, Cancer, Boston Medical Center, CME, GE HealthCare, Woman, Publication, Malignancy, SBI, Breast cancer, Workplace, Research, Pathology, Artificial intelligence, DBT, CEM, Patient, Biopsy, Diagnosis, Self-assessment, Breast, Medical imaging

GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024.
  • This year’s showcase will feature the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite* and Pristina Bright** offering to demonstrate the company’s personalized approach to transforming breast cancer imaging.
  • The truck is equipped with the Senographe Pristina and Invenia ABUS to ensure accurate and efficient screenings.
  • *MyBreastAI suite is a commercial offering that includes GE HealthCare’s Edison Health Services platform, ProFound AI® for DBT, SecondLook for 2D Mammography and PowerLook® Density Assessment.

Boston Medical Center Study Furthers Understanding of Lung Regeneration

Retrieved on: 
Monday, April 22, 2024
Mortality, Boston Medical Center, BMC, Cell Stem Cell, Cell, Chronic obstructive pulmonary disease, Boston University, Transplant, Regenerative medicine, Health, Bacteria, Respiratory disease, MD, Doctor of Philosophy, Disease, Respiratory system, Engineering, Acute respiratory distress syndrome, Pulmonary fibrosis, AT1, Science, Medicine, Knowledge, Infection, COPD, Vaccine

BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).

Key Points: 
  • BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).
  • As science and medicine have progressed, researchers have identified a clear need for additional knowledge about lung cells to help improve patient health.
  • "Uncovering the ability to generate human alveolar epithelial type I cells (AT1s), and similar cell types, from pluripotent stem cells (iPSCs), has expanded our knowledge of biological processes and can significantly improve disease understanding and management," said Darrell Kotton, MD, Director, Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center.
  • This new study also furthers the CReM's goal of generating every human lung cell type from iPSCs as a pathway to improving disease management and provides a source of cells for future transplantation to regenerate damaged lung tissues in vivo.

March of Dimes Awards Two Basil O'Connor Grants to Study Triggers of Labor Onset, Barriers to Postpartum Heart Health

Retrieved on: 
Tuesday, April 16, 2024
Mortality, Randomized controlled trial, Mayo Clinic, Boston Medical Center, Preterm birth, Boston University, Risk, Pregnancy, Woman, Blood, Health, Placenta, Doctor of Philosophy, Research, HDP, Infant, Obstetrics, Gynaecology, DNA, Therapy, Senior counsel, MPH, Immunology, Hypertension, Data collection, Pre-eclampsia, Disease, Assistant, RCT, Basil, Nursing

Dr. Enninga's work will focus on the role of cell free (cf) fetal DNA on labor and preterm birth, which occurs before 37 weeks of pregnancy.

Key Points: 
  • Dr. Enninga's work will focus on the role of cell free (cf) fetal DNA on labor and preterm birth, which occurs before 37 weeks of pregnancy.
  • The placenta releases cf fetal DNA into the maternal bloodstream during pregnancy.
  • Her Basil O'Connor work will set the foundation for a planned randomized controlled trial (RCT) of postpartum patient navigation set to take place in 2027.
  • Together, both are supporting our mission to reduce preventable maternal and infant mortality and morbidity."

XORTX Announces New Clinical Advisory Board Member

Retrieved on: 
Wednesday, March 27, 2024
Sanofi, Database, Internal medicine, Critical Path Institute, XRX, TEMPO, Patient, Research, Biomarker, TAME, Polycystic kidney disease, National Institutes of Health, MD, Kidney disease, European Medicines Agency, Publication, PKD, Clinical trial, Boston Medical Center, Therapy, Grady Memorial Hospital, FDA, Food, Pharmaceutical industry

CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.

Key Points: 
  • CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
  • Dr. Allen Davidoff stated, “We are excited that Dr. Ron Perrone has agreed to join XORTX’s Clinical Advisory Board.
  • Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease.
  • We are privileged to have Dr. Perrone join our esteemed Clinical Advisory Board alongside current members, Dr. Petter Bjornstad, Dr. Richard Johnson, Dr. Federico Maese, Dr. Anjay Rostogi and Dr. Charles Edelstein.

Boston Medical Center Advances Equitable Patient Access with BMC Hospital at Home

Retrieved on: 
Wednesday, April 3, 2024
Research, Boston Medical Center, Pneumonia, Home, Bed, Partnership, Patient, BMC, MD, Medical Center, MBA, Heart failure, Dehydration, Hospital, Multimedia, Nursing

BOSTON, April 3, 2024 /PRNewswire/ -- Boston Medical Center (BMC) today announced its new Hospital at Home service, which will give eligible patients the opportunity to receive high-acuity, hospital-level healthcare from leading providers and recover in the comfort of their own homes with this new remote acute care unit. The clinical offering, called Boston Medical Center Hospital at Home, will improve care access, equity in care options, and convenience for patients.

Key Points: 
  • The clinical offering, called Boston Medical Center Hospital at Home, will improve care access, equity in care options, and convenience for patients.
  • Research shows that hospital-level care in the home improves access to care, and patients experience shorter recovery times with fewer complications.
  • "BMC Hospital at Home is anchored in BMC's commitment to deliver transformative models of care that improve access and equity across the communities we serve," said Alastair Bell, MD, MBA, President & CEO of Boston Medical Center Health System.
  • In addition to launching BMC Hospital at Home, BMC has continued to identify areas of opportunity to increase patient capacity and manage inpatient flow to ensure it continues to offer excellent care to all.

Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic

Retrieved on: 
Monday, March 4, 2024
University of Texas System, Bangladesh Technical Education Board, School, Boston Medical Center, Dementia, NIH, University, Cerebrovascular disease, SAB, Stroke, Frank, Radiology, History, Biomedical sciences, Clinical, UNC, Clinical trial, Knowledge, McGovern Medical School, Pediatrics, Research, BMC, Pharmaceutical industry

BOSTON and ATHENS, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, is pleased to announce the formation of its Stroke Advisory Board (SAB). Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.

Key Points: 
  • Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.
  • The newly established board features renowned figures in the medical and scientific community, each bringing a wealth of knowledge and experience to Aruna Bio.
  • “AB126 is making history with the first exosome therapy to enter human clinical trials for a neurological condition,” said Stephen From, Chief Executive Officer at Aruna Bio.
  • “This represents a significant step forward in our quest to transform the treatment landscape for stroke and other neurodegenerative diseases.

Immix Biopharma 12 Month Review Progress Update

Retrieved on: 
Wednesday, February 21, 2024
Boston University, Research, Autoimmune disease, Toxicity, Doctor of Philosophy, Boston Medical Center, PMID, Health, Multiple myeloma, Patient, Poster, Blood, Investigational New Drug, Presentation, Bank, Johnson & Johnson, GMP, BCMA, Amyloidosis, BioMarin Pharmaceutical, Autoimmunity, MBBS, Pfizer, ASH, European, IMS, Conference, ODD, Haematologica, IND, Public, Gene, MD, FDA, Food, U.S. FDA, Cell, ALA, Letter, Society, Publication, BMC, Pharmaceutical industry

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.

Key Points: 
  • LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
  • “The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease.
  • NXC-201 is the first and only ‘Single-Day CRS‘ CAR-T, a critical advancement for autoimmune diseases like AL Amyloidosis,” said Ilya Rachman, MD PhD CEO Immix Biopharma.
  • As we reflect on the last 12 months of progress, we wish to connect with you offering an update on Immix Biopharma.

Sleep Apnea Symptoms Linked to Memory and Thinking Problems

Retrieved on: 
Monday, March 4, 2024
Social media, Nervous system, Alzheimer's disease, Boston Medical Center, CPAP, Dementia, Education, Sleep apnea, Blood, Quality of life, Thought, Sleep, Continuous positive airway pressure, Stroke, Confusion, Risk, Annual general meeting, DSM-IV codes, Migraine, AAN, Multiple sclerosis, Parkinson's disease, Memory, Concussion, MPH, Headache, Epilepsy, Brain, Research, American Academy, Pharmaceutical industry

"Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."

Key Points: 
  • "Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."
  • Of those with symptoms, 357 people, or 33%, reported memory or thinking problems compared to 628 people, or 20% of people without sleep apnea symptoms.
  • After adjusting for other factors that could affect memory and thinking problems, such as age, race, gender and education, researchers found that people who reported sleep apnea symptoms were about 50% more likely to also report having memory or thinking problems compared to people who did not have sleep apnea symptoms.
  • Additional studies are needed following people's sleep apnea, memory and thinking symptoms over time.

Paul Tornetta III, MD, PhD, FAAOS, Named 92nd President of the American Academy of Orthopaedic Surgeons

Retrieved on: 
Wednesday, February 14, 2024
Knowledge, Boston University, SAN, ROCK, Medicine, Doctor of Philosophy, Boston Medical Center, ABOS, Journal of Orthopaedic Trauma, MD, Teaching hospital, Orthopedic surgery, Hospital, Surgeon, Education, SUNY Downstate Medical Center, DSM-IV codes, Annual general meeting, State university system, AOA, Council, Patient, Teaching, OTA, Trauma, Kings County Hospital Center, Curriculum, AAOS, American Academy

SAN FRANCISCO, Feb. 14, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced Boston orthopaedic trauma surgeon Paul Tornetta III, MD, PhD, FAAOS, as its new president for 2024-2025.

Key Points: 
  • SAN FRANCISCO, Feb. 14, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced Boston orthopaedic trauma surgeon Paul Tornetta III, MD, PhD, FAAOS, as its new president for 2024-2025.
  • In his acceptance speech, Dr. Tornetta said, "I am honored and humbled to serve as AAOS president.
  • As orthopaedic surgeons, we share a strong bond based in helping others.
  • He is past president of the Orthopaedic Trauma Association (OTA) and served on the executive committee of the American Orthopaedic Association (AOA) for more than a decade.

Dr. Ann McClain Terrell Joins The Goddard School’s Educational Advisory Board

Retrieved on: 
Tuesday, February 6, 2024
Preschool, Education, Multimedia, Milwaukee Public Schools, Research, Intervention, GSL, Father, Goddard School, Yale school, Child, Yale School of Medicine, Pediatrics, Faculty, Cardinal Stritch University, Physician, Boston Medical Center, Psychology, Cal, University, Health, Educational leadership, Student, NAEYC, EAB, Conference, National Association, Nursing

Goddard Systems, LLC (GSL), manager of The Goddard School franchise system, welcomes Dr. Ann McClain Terrell to its Educational Advisory Board (EAB).

Key Points: 
  • Goddard Systems, LLC (GSL), manager of The Goddard School franchise system, welcomes Dr. Ann McClain Terrell to its Educational Advisory Board (EAB).
  • View the full release here: https://www.businesswire.com/news/home/20240206624021/en/
    Dr. Ann McClain Terrell, The Goddard School Educational Advisory Board Member (Photo: Business Wire)
    With five decades of professional experience, Dr. Terrell is one of the nation’s preeminent early childhood education leaders.
  • “On behalf of our entire Goddard team, from our corporate staff to the franchisees and faculty at more than 600 Goddard Schools, I am honored to welcome Dr. Terrell to our Educational Advisory Board,” said Dr. Lauren Loquasto, senior vice president and chief academic officer, GSL.
  • “I admire The Goddard School and its commitment to continuously innovating and evolving to deliver the best educational program to its students,” said Dr. Terrell.